The FGFR4KV550L and FGFR4KV550E studies assessed substrate phosphorylation following FIIN-2 treatment. Both reported effective inhibition of substrate phosphorylation by all mutants, including the V550L gate-keeper mutant. In a chicken SRC assay, FIIN-2 was moderately potent against SRC, with an IC50 of 330 nM. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Inhibition of Mutant Substrate Phosphorylation
Cell-based study · FGFR4KV550L [1]
In the FGFR4KV550L model, FIIN-2 effectively inhibited substrate phosphorylation by all mutants, including the V550L gate-keeper mutant.
Literature-Reported Treatment Conditions
- Reported limits
- Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: FIIN-2
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S20); Methods > Peptide Substrate Phosphorylation Assay by Native Gel and MALDI-TOF Mass Spectrometry (S81); Figure 3 legend (S104)
substrate phosphorylation activities: substrate phosphorylation activities — Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S20); Figure 3 legend (S104)
Activity Against Chicken SRC
Cell-based study · chicken SRC (residues 251−533) [2]
FIIN-2 was incubated with chicken SRC and was moderately potent against SRC, with an IC50 of 330 nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01 nM to 25 μM
- Exposure duration
- for half an hour at room temperature
- Method
- incubated with kinases
- Vehicle
- 4% DMSO
- Reported limits
- Not stated in the sentences used: control.
Methods and source locations
Compound reported in the paper: FIIN-2
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Inhibitory potency of FIIN-2, TAS-120 and PRN1371 against FGFRs and SFKs (S15); Methods > Protein expression and purification (S69); Methods > Kinase inhibition assay (S90, S91, S93, S94, S96, S97)
IC50 values: IC50 values — Results > Inhibitory potency of FIIN-2, TAS-120 and PRN1371 against FGFRs and SFKs (S15); Methods > Kinase inhibition assay (S97)
Peptide Substrate Phosphorylation in a Mutant Model
Cell-based study · FGFR4KV550E [1]
In the FGFR4KV550E model, peptide substrate phosphorylation was assessed following FIIN-2 treatment. The reported result was effective inhibition of substrate phosphorylation by all mutants, including the V550L gate-keeper mutant.
Literature-Reported Treatment Conditions
- Reported limits
- Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: FIIN-2
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S17, S20); Methods > Peptide Substrate Phosphorylation Assay by Native Gel and MALDI-TOF Mass Spectrometry (S81)
Peptide substrate phosphorylation activities: Peptide substrate phosphorylation activities — Results > The FGFR4K Gate-Keeper Mutations Confer Resistance to Ponatinib but Are Sensitive to FIIN-2 (S20); Methods > Peptide Substrate Phosphorylation Assay by Native Gel and MALDI-TOF Mass Spectrometry (S81)